In this new study, Dr. Katrina Perehudoff examines how the European Union can—and should—contribute to improving global access to medicines for persons with disabilities living in low- and middle-income countries (LMICs), based on its legal commitments under the Convention on the Rights of Persons with Disabilities.

As the first regional international organisation to accede to a United Nations human rights treaty, the EU represents a unique legal case. This paper explores whether, and how, its international human rights obligations extend beyond its own borders—particularly in relation to pharmaceutical policy, intellectual property, and technology transfer. The paper explores a legal framework grounded in the CRPD to assess the EU’s responsibilities through two major policy initiatives:

  • The EU’s internal joint COVID-19 vaccine procurement strategy
  • The external BioNTainer vaccine production initiative in Africa, implemented under Team Europe

This research highlights the importance of aligning global health governance, disability rights, and pharmaceutical policy. It contributes to ongoing international discussions on how high-income actors—including regional organisations like the EU—can better support equitable access to medicines worldwide through rights-based approaches.

This paper was published in a Symposium entitled ‘Public Health, Markets, and Law’ published in the Journal of Law, Medicine & Ethics, and guest edited by Dr. Mina Hosseini and Prof. Imelda Maher of University College Dublin.

This paper was published as part of Dr. Perehudoff’s NWO Veni project ‘Global access to medicines through EU law and policy’ and the END VOC research consortium, funded in part by the European Union under grant agreement no. 101046314 (END-VOC project).